Israeli-led Nature study tests blood test for early breast cancer and recurrence risk
A Nature study by Weizmann Institute and Hebrew University researchers found that epigenetic markers in blood could distinguish early breast cancer from healthy samples and flag recurrence risk. The work is early, and outside and study voices say larger studies are needed.
1 / 2
The story, neutrally told
Mixed · 2Researchers led by the Weizmann Institute of Science and the Hebrew University of Jerusalem published a study in Nature describing a blood test that can distinguish women with early-stage breast cancer from healthy women and indicate which patients face a higher risk of recurrence. NewsweekN “The study, published in Nature and led by researchers at Israel's Hebrew University of Jerusalem and the Weizmann Institute of Science” Read at Newsweek ↗ JNSR “The study, published in the peer-reviewed journal Nature, was led by researchers from the Weizmann Institute of Science in Rehovot and the Hebrew University of Jerusalem.” Read at JNS ↗ Mixed · 2The test reads epigenetic signatures, chemical marks that control gene activity, on cell-free nucleosomes (DNA wrapped around proteins) that are released into blood when cells die; the team adapted a technology called EPINUC that uses less than one millilitre of plasma. JNSR “It analyzes cell-free nucleosomes—fragments of DNA wrapped around proteins and released when cells die.” Read at JNS ↗ NewsweekN “Using single-molecule microscopy and fluorescent labels, they measured dozens of epigenetic markers across millions of nucleosomes.” Read at Newsweek ↗ Mixed · 2The researchers first analysed 12 surgically removed, previously untreated tumours, mostly luminal (hormone-receptor-positive), and found a population of cells with a basal-like profile, a type generally linked to more aggressive disease; in laboratory models an aggressive population always eventually emerged, even from non-aggressive cells. JNSR “They analyzed 12 surgically removed, previously untreated breast tumors, most of them luminal tumors.” Read at JNS ↗ NewsweekN “Laboratory models starting with nonaggressive breast cancer cells eventually produced this aggressive population, making them a hidden threat.” Read at Newsweek ↗
Mixed · 2In an initial group of 77 breast cancer patients and 30 healthy women, the test separated cancer from healthy samples; Newsweek reports AI models distinguished early-stage cancers (confined to the breast, no more than 2 cm) with 95 percent accuracy. NewsweekN “The AI models were able to distinguish women with early-stage breast cancer from healthy women with 95 percent accuracy.” Read at Newsweek ↗ JNSR “In an initial group of 77 women with luminal breast cancer and 30 healthy women” Read at JNS ↗ Right · 1JNS reports that on a further 188 luminal breast cancer samples, a model trained on 75% of the data and tested on 25% reached an area under the curve (AUC) of 0.96, and a separate Mayo Clinic set gave 0.98. JNSR “A model trained on 75% of the data and tested on the remaining 25% achieved an area under the curve (AUC) of 0.96. A separate set of samples from the Mayo Clinic produced an AUC of 0.98.” Read at JNS ↗ Mixed · 2For recurrence, the 77-patient Mayo Clinic group had at least five years of follow-up; a model using the blood signature predicted relapse with 81 percent accuracy (AUC 0.81), and JNS says this outperformed models based on stage, grade and subtype, while a smaller separate group gave an AUC of 0.92. NewsweekN “allowed the researchers to distinguish, with 81 percent accuracy, between patients whose cancer returned during follow-up and those whose disease did not.” Read at Newsweek ↗ JNSR “outperforming models based on conventional factors such as cancer stage, tumor grade and subtype. In a smaller, separate group of patients, the test achieved an AUC of 0.92.” Read at JNS ↗
Mixed · 2Professor Guy Ron of the Hebrew University said that the more prevalent the aggressive-cell signature was in blood, the greater the risk of the disease returning; Newsweek adds the test flagged recurrence risk in some patients considered low risk by conventional measures. JNSR “the more prevalent it was, the greater the risk that the disease would come back,” Professor Guy Ron of the Hebrew University said.” Read at JNS ↗ NewsweekN “The test also identified potential recurrence risk among some patients considered low risk by conventional measures.” Read at Newsweek ↗ Mixed · 2Professor Efrat Shema of the Weizmann Institute said evidence is mounting that cancer cells use epigenetic flexibility to become more aggressive and evade treatment, and that the findings could help predict recurrence and search for ways to prevent it; JNS adds the work points to a possible therapy targeting these chemical changes. NewsweekN “"Evidence is mounting that cancer cells exploit their epigenetic flexibility to change their behavior, become more aggressive and evade treatment,"” Read at Newsweek ↗ JNSR “The research also points to a potential new therapeutic approach” Read at JNS ↗ Mixed · 2Context: breast cancer is the most commonly diagnosed cancer among women, with about 2.3 million new cases worldwide in 2022, and Newsweek says it returns in an estimated 20 to 40 percent of cases despite apparently successful treatment. JNSR “approximately 2.3 million new cases recorded worldwide in 2022” Read at JNS ↗ NewsweekN “breast cancer returns in an estimated 20 to 40 percent of cases” Read at Newsweek ↗
Centre · 1Dr. Lucy Hooper, a general practitioner and co-founder of Coyne Medical, told Newsweek that larger studies are needed before routine use, noting the study was early, retrospective and largely of hormone-receptor-positive cancers, with samples taken before surgery, and that there is no convincing evidence yet that changing treatment after an early positive result improves outcomes. NewsweekN “Hooper cautions that the study was early and retrospective, and largely involved hormone-receptor-positive breast cancers.”“What we do not yet have is convincing evidence that changing treatment in response to an early positive result improves long-term outcomes” Read at Newsweek ↗ Right · 1The researchers themselves stressed that further studies are needed to validate the findings and establish whether EPINUC can be used in clinical practice. JNSR “The researchers stressed that further studies are needed to validate the findings and establish whether EPINUC can be used in clinical practice.” Read at JNS ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left0 outlets
No left outlet in our sources has covered this story yet.
Centre1 outlet
- Framing
- Patient-facing explainer on a possible early-detection and recurrence-risk test, balanced by an outside clinician's caveats.
- Emphasis
- Accuracy figures, mammography limits in dense breasts, and the need for larger studies.
- Leaves out or plays down
- Omits the AUC figures from validation sets and the 12-tumour analysis detail.
- Charged language
- “hidden threat”
Right1 outlet
- Framing
- National-achievement angle: an Israeli-developed test, relayed from the TPS-IL news service, with technical detail.
- Emphasis
- Methodology, AUC scores across cohorts, and potential therapeutic implications.
- Leaves out or plays down
- Includes no independent expert comment, and states researchers' caveats only briefly; omits that samples were taken before surgery and the study was retrospective.
- Charged language
- “Israeli blood test”
What every side reports
- The study was published in Nature and led by the Weizmann Institute of Science and the Hebrew University of Jerusalem.
- The test analyses epigenetic marks on cell-free nucleosomes in blood.
- It was tested on 77 breast cancer patients (Mayo Clinic) and 30 healthy women, and predicted recurrence with about 0.81 accuracy/AUC.
- Further research is needed before clinical use.
North America1 outlet
Newsweek presents it as a health explainer with an outside clinician's caution.
“larger studies are needed before the test can be employed routinely” — Newsweek
Newsweek
Israel1 outlet
JNS stresses the Israeli origin and the technical results.
“Israeli researchers have developed a blood test” — JNS
JNS
Left0 articles
No coverage yet.
Centre1 article
-
Breast Cancer Blood Test Spots Hidden Threat That Could Cause It To Return
Mixed Hopeful report on the findings tempered by an outside doctor's caution about early, retrospective evidence.

Right1 article
-
JNSR ·
Israeli blood test could help predict breast cancer recurrence
Sympathetic Presents the study as an Israeli scientific advance, detailing methods and performance with researchers' quotes.

- 13 Nov 16:08 First NewsweekN Breast Cancer Blood Test Spots Hidden Threat That Could Cause It To Return
- 16 Nov 05:07 +60h 59m JNSR Israeli blood test could help predict breast cancer recurrence
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…